Eprex — supply status, manufacturers & alternatives

Eprex

—

🇦🇺 AUST R 65442 · Janssen-Cilag Pty Ltd

In supply · Australia

In supply · 🇦🇺 Australia

In supply in Australia

No active shortage reported.

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Registrations on file
Active ingredient (INN)	Eprex
Therapeutic category	Auto-created by Agencia Española de Medicamentos — Problemas de Suministro scraper
Controlled substance	No
Marketing-authorisation holders	JANSSEN-CILAG LIMITED, Janssen-Cilag Pty Ltd, JANSSEN INC

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Other markets

🇫🇷 FR

€87.93

Retail price

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 3 resolved events

◷

1–2 months

Historical pattern from resolved shortage records — not a prediction of this event.

Shortage status by regulator official notices

🇪🇸

Spain

AEMPS · 6h ago

Resolved

Recalls official enforcement reports

🇳🇿

Eprex

Cilag AG · Oct 2015

Class IIIdetails ↗

🇳🇿

Eprex

Cilag AG · May 2015

Class IIIdetails ↗

Verified timeline regulator events

🇪🇸 11 Mar 2026

Shortage resolved

🇪🇸 23 Feb 2026

Shortage resolved

🇪🇸 27 Jan 2026

Shortage resolved

Sources official regulators

🇪🇸

AEMPS

verified 6h ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders25 registrations · 3 MA holders

Product	Strength	Form	Market	MA holder	Status
EPREX 4,000 IU/ML SOLUTION FOR INJECTION IN PFS	000 IU	injection	🇬🇧 GB	JANSSEN-CILAG LIMITED	Active
EPREX 10,000 IU/ML, SOLUTION FOR INJECTION IN PFS	000 IU	injection	🇬🇧 GB	JANSSEN-CILAG LIMITED	Active
EPREX 40,000 IU/ML SOLUTION FOR INJECTION IN PFS	000 IU	injection	🇬🇧 GB	JANSSEN-CILAG LIMITED	Active
EPREX epoetin alfa	1000IU	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
EPREX epoetin alfa	2000IU	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
EPREX epoetin alfa	3000IU	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
EPREX epoetin alfa	4000IU	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
EPREX epoetin alfa	10000IU	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
EPREX epoetin alfa	20000IU	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
EPREX epoetin alfa	40000IU	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
EPREX epoetin alfa	5000IU	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
EPREX epoetin alfa	6000IU	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
EPREX epoetin alfa	8000IU	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
EPREX epoetin alfa	30000IU	—	🇦🇺 AU	Janssen-Cilag Pty Ltd	Active
Eprex Sterile	1000IU	solution	🇨🇦 CA	JANSSEN INC	Active

+10 more registrations on file

Mederti Drug Report

Generated 6 July 2026 · Australia market · 1 regulatory source

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.